Psilocybin Fibromyalgia Treatment With Screening and Integration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for fibromyalgia provide modest benefits but are accompanied by substantial side effects, and there is a need for a more effective and side-effect-reduced therapeutic approach.
Innovation Solution
Administering psilocybin or its metabolite to induce a dissociative state, followed by integration sessions and assessment of indicators, to treat fibromyalgia symptoms, while excluding subjects with certain contraindications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments for fibromyalgia are used, then some symptom relief is achieved, but substantial side effects occur
Solution Approach 1:
The patent changes the chemical parameter by substituting conventional fibromyalgia medications with psilocybin, a psychedelic compound with a different mechanism of action. This parameter change allows achieving symptom relief through serotonin receptor modulation rather than conventional pain management pathways, thereby reducing side effects while maintaining treatment effectiveness
Solution Approach 2:
The patent introduces psilocybin as an intermediary substance that mediates treatment between the patient and their symptoms. Psilocybin acts as a mediator by inducing temporary dissociative states that facilitate psychological processing and symptom management, offering an alternative pathway that avoids the side effects of direct pharmacological pain management
2Reliability
If psilocybin is administered to induce dissociative state, then significant symptom improvement is achieved, but treatment complexity increases due to integration sessions and assessments
Solution Approach 1:
The patent segments the treatment protocol into distinct phases: pre-treatment screening, psilocybin administration, dissociative state experience, integration sessions, and follow-up assessments. This segmentation allows each component to be optimized independently and facilitates systematic management of the complex treatment process, making the overall protocol more manageable despite its multifaceted nature
Solution Approach 2:
The patent implements preliminary actions including comprehensive subject screening for contraindications, preparation of the treatment environment, and pre-treatment counseling before psilocybin administration. These preliminary steps ensure patient safety and optimize treatment outcomes, justifying the increased protocol complexity by preventing adverse events and enhancing therapeutic effectiveness
Data Source
AI summary
Provided are methods for treating fibromyalgia or one or more symptoms thereof, that involve the administration of psychedelics, such as psilocybin or a metabolite thereof, and related uses of the psychedelics. The disclosure in some aspects also relates to methods for identifying subjects for treatment of fibromyalgia with administration of psychedelics. In some aspects, the treatment also involves psychotherapy. In some aspects, the subject receiving the treatment is assessed for various indicators, such as observer-rated and subject-reported outcomes, biological and clinical indicators, and combinations thereof.